Zomedica (ZOMDF) Stock Price, News & Analysis

Company Overview

Zomedica Corp. is a veterinary health company that develops, acquires, and commercializes diagnostic and therapeutic products for companion-animal and equine practitioners. Its offerings are designed to help veterinarians improve clinical decision-making and deliver noninvasive treatments in practice.

The company’s portfolio includes the TRUFORMA point-of-care diagnostic platform, which is intended to support testing for certain veterinary conditions, as well as therapeutic technologies such as PulseVet’s shock-wave therapy systems and Assisi Animal Health’s pulsed electromagnetic field products. Zomedica markets these products primarily through veterinary practices and related animal-health channels.

Zomedica has expanded beyond its original focus on veterinary pharmaceuticals through acquisitions and strategic investments in diagnostic, therapeutic, and biomedical-device businesses. The company is based in Ann Arbor, Michigan, and serves the veterinary market in the United States and other markets through its commercial operations and distribution relationships.

Key Stats

• Today's Range: $0.09 to $0.10
• 50-Day Range: $0.07 to $0.10
• 52-Week Range: $0.07 to $0.16
• Volume: 317,865 shs
• Average Volume: 1.05 million shs
• Market Capitalization: $93.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Zomedica Stock Analysis - MarketRank™

Zomedica scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Zomedica.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Zomedica has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Zomedica has been sold short.

Short Interest Ratio / Days to Cover

Zomedica has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Zomedica has recently decreased by 88.11%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zomedica does not currently pay a dividend.

Dividend Growth

Zomedica does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.18

News Sentiment

Zomedica has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Zomedica this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Zomedica to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Zomedica insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.75% of the stock of Zomedica is held by insiders.

Percentage Held by Institutions

8.95% of the stock of Zomedica is held by institutions.

Company Calendar

• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ZOMDF
• Previous Symbol: OTC:ZOMDF
• CIK: 1684144
• Web: www.zomedica.com
• Phone: 734 369 2555
• Fax: N/A
• Employees: 50
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$81.86 million
• Net Margins: -41.63%
• Pretax Margin: -41.71%
• Return on Equity: -14.71%
• Return on Assets: -13.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.09
• Quick Ratio: 5.46

Sales & Book Value

• Annual Sales: $32.03 million
• Price / Sales: 2.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 979,950,000
• Free Float: 913,803,000
• Market Cap: $93.10 million
• Optionable: N/A
• Beta: 1.34